These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 7618280

  • 1. High-level expression of the measles virus nucleocapsid protein by using a replication-deficient adenovirus vector: induction of an MHC-1-restricted CTL response and protection in a murine model.
    Fooks AR, Schadeck E, Liebert UG, Dowsett AB, Rima BK, Steward M, Stephenson JR, Wilkinson GW.
    Virology; 1995 Jul 10; 210(2):456-65. PubMed ID: 7618280
    [Abstract] [Full Text] [Related]

  • 2. Single oral immunization with replication deficient recombinant adenovirus elicits long-lived transgene-specific cellular and humoral immune responses.
    Sharpe S, Fooks A, Lee J, Hayes K, Clegg C, Cranage M.
    Virology; 2002 Feb 15; 293(2):210-6. PubMed ID: 11886240
    [Abstract] [Full Text] [Related]

  • 3. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo.
    Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE, Smith JF.
    Virology; 1997 Dec 22; 239(2):389-401. PubMed ID: 9434729
    [Abstract] [Full Text] [Related]

  • 4. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector.
    Juillard V, Villefroy P, Godfrin D, Pavirani A, Venet A, Guillet JG.
    Eur J Immunol; 1995 Dec 22; 25(12):3467-73. PubMed ID: 8566039
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of replication-defective adenovirus-vectored vaccines: protection following intramuscular injection is linked to promoter efficiency in muscle representative cells.
    Ambriović A, Adam M, Monteil M, Paulin D, Eloit M.
    Virology; 1997 Nov 24; 238(2):327-35. PubMed ID: 9400605
    [Abstract] [Full Text] [Related]

  • 6. Replication-incompetent adenoviruses as vectors for protective immunization against measles virus infection.
    Schindler C, Fooks A, Stephenson J, Liebert UG.
    Behring Inst Mitt; 1994 Dec 24; (95):109-15. PubMed ID: 7755504
    [Abstract] [Full Text] [Related]

  • 7. A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer.
    Riezebos-Brilman A, Walczak M, Regts J, Rots MG, Kamps G, Dontje B, Haisma HY, Wilschut J, Daemen T.
    Gene Ther; 2007 Dec 24; 14(24):1695-704. PubMed ID: 17928874
    [Abstract] [Full Text] [Related]

  • 8. A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes.
    Lorin C, Delebecque F, Labrousse V, Da Silva L, Lemonnier F, Brahic M, Tangy F.
    Vaccine; 2005 Aug 22; 23(36):4463-72. PubMed ID: 15993518
    [Abstract] [Full Text] [Related]

  • 9. Induction of humoral and cellular immune responses against the nucleocapsid of bovine viral diarrhea virus by an adenovirus vector with an inducible promoter.
    Elahi SM, Shen SH, Talbot BG, Massie B, Harpin S, Elazhary Y.
    Virology; 1999 Aug 15; 261(1):1-7. PubMed ID: 10441551
    [Abstract] [Full Text] [Related]

  • 10. Anti-viral immunity induced by recombinant nucleoprotein of influenza A virus. III. Delivery of recombinant nucleoprotein to the immune system using attenuated Salmonella typhimurium as a live carrier.
    Tite JP, Gao XM, Hughes-Jenkins CM, Lipscombe M, O'Callaghan D, Dougan G, Liew FY.
    Immunology; 1990 Aug 15; 70(4):540-6. PubMed ID: 2168340
    [Abstract] [Full Text] [Related]

  • 11. Construction of vaccinia virus recombinants expressing several measles virus proteins and analysis of their efficacy in vaccination of mice.
    Wild TF, Bernard A, Spehner D, Drillien R.
    J Gen Virol; 1992 Feb 15; 73 ( Pt 2)():359-67. PubMed ID: 1538193
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Expression and immune response to hepatitis C virus core DNA-based vaccine constructs.
    Tokushige K, Wakita T, Pachuk C, Moradpour D, Weiner DB, Zurawski VR, Wands JR.
    Hepatology; 1996 Jul 15; 24(1):14-20. PubMed ID: 8707253
    [Abstract] [Full Text] [Related]

  • 17. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier.
    Xiang ZQ, Yang Y, Wilson JM, Ertl HC.
    Virology; 1996 May 01; 219(1):220-7. PubMed ID: 8623532
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Identification of a cytotoxic T-cell epitope on the recombinant nucleocapsid proteins of Rinderpest and Peste des petits ruminants viruses presented as assembled nucleocapsids.
    Mitra-Kaushik S, Nayak R, Shaila MS.
    Virology; 2001 Jan 05; 279(1):210-20. PubMed ID: 11145903
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of recombinant vaccinia virus--measles vaccines in infant rhesus macaques with preexisting measles antibody.
    Zhu Yd, Rota P, Wyatt L, Tamin A, Rozenblatt S, Lerche N, Moss B, Bellini W, McChesney M.
    Virology; 2000 Oct 10; 276(1):202-13. PubMed ID: 11022008
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.